Turkey antirheumatic drugs market was valued at US$509.792 million in 2020.
The major factor driving the antirheumatic drugs market growth in Turkey includes the rising risk of the reintroduction of localized outbreaks of malaria throughout the country. However, there has been a dramatic decrease in the number of malaria cases and their active foci. Furthermore, the high prevalence of non-communicable diseases in the country, such as heart diseases, cancer, diabetes, osteoarthritis, and osteoporosis, among others, is also considered to be one of the key factors bolstering the antirheumatic drugs market growth in the country during the next five years. According to data from the World Health Organization, non-communicable diseases account for more than 80% of the deaths in the country. Furthermore, the government initiatives to respond to the growing burden of non-communicable diseases in the country are also projected to significantly drive market growth as numerous plans implemented by the country’s Ministry of Health aimed to improve the healthcare sector and its services. For instance, the NCD action plan for 2017-2025. Additionally, the growing geriatric population in the country also supports the market for antirheumatic drugs in Turkey during the next five years. For example, the population aged 65 and above (% of the total population) reached 8.483% by 2018 from 6.993% in 2008.
Turkey's antirheumatic drugs market has been segmented based on the type of disease, type of molecule, and sales channel. By type of disease, the market has been segmented as osteoarthritis, rheumatoid arthritis, gout, lupus, and others. By type of molecule, Turkey antirheumatic drugs market has been classified into pharmaceuticals and biopharmaceuticals. The market segmentation has also been done by sales channels such as prescription and over-the-counter (OTC).
Key Developments:
COVID 19 SCENARIO
COVID has negatively affected Turkey's antirheumatic drugs market. Patients with rheumatoid arthritis who contract COVID-19 infection, according to the Lancet Rheumatology 2020, are at significant risk of developing severe symptoms and consequences. COVID-19 is being studied as a potential therapy with some DMARDs routinely used to treat rheumatoid arthritis, such as hydroxychloroquine medication. Non-COVID patients had less access to hospitals. As a result, there was a decline in rheumatic diagnoses, resulting in lower demand for antirheumatic drugs in the region. Other commonly used medications, such as biologics targeting interleukin (IL)-6 (sarilumab, tocilizumab) and IL-1 (anakinra), are also being studied in COVID-19 patients. As a result, COVID-19 infection boosted rheumatoid arthritis medicine manufacturers' growth prospects during the anticipated period.
Segmentation